Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae

Introduction: The aim of this work was to study the ability of ciprofloxacin to restrict the development of resistant mutants of Escherichia coli and Klebsiella pneumoniae through determination of the Mutant Prevention Concentration (MPC). Methodology: We studied 140 strains of E. coli and 86 strai...

Full description

Saved in:
Bibliographic Details
Main Authors: Ziad Daoud, Elie Salem Sokhn, Eid Azar, Khalil Masri, Shira Doron
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2014-02-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/3164
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850036369164861440
author Ziad Daoud
Elie Salem Sokhn
Eid Azar
Khalil Masri
Shira Doron
author_facet Ziad Daoud
Elie Salem Sokhn
Eid Azar
Khalil Masri
Shira Doron
author_sort Ziad Daoud
collection DOAJ
description Introduction: The aim of this work was to study the ability of ciprofloxacin to restrict the development of resistant mutants of Escherichia coli and Klebsiella pneumoniae through determination of the Mutant Prevention Concentration (MPC). Methodology: We studied 140 strains of E. coli and 86 strains of K. pneumoniae with different profiles of sensitivity to fluoroquinolones and extended spectrum beta lactamase (ESBL) production. The MPCs were determined using an inoculum of 1010 CFU/ml in Mueller-Hinton agar plates with serial concentrations of ciprofloxacin. Results: Ciprofloxacin-susceptible ESBL-producing strains showed a higher MPC for ciprofloxacin (P <0.001) than ciprofloxacin-susceptible non ESBL-producing strains, while ciprofloxacin-resistant ESBL-producing and non ESBL-producing strains did not significantly differ. The presence of qnr variants was associated with elevated MPCs. This was observed for both tested organisms. Conclusions: Our study helps to explain the frequent finding of resistance to fluoroquinolones in ESBL-producing strains. Consequently, the use of concentrations of ciprofloxacin higher than the MIC in order to prevent the recovery and growth of resistant mutants is recommended.
format Article
id doaj-art-51a5fc62a17d48779a9b0b51f58c64f0
institution DOAJ
issn 1972-2680
language English
publishDate 2014-02-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-51a5fc62a17d48779a9b0b51f58c64f02025-08-20T02:57:12ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802014-02-0180210.3855/jidc.3164Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniaeZiad Daoud0Elie Salem Sokhn1Eid Azar2Khalil Masri3Shira Doron4University of Balamand, Tripoli, LebanonUniversity of Surrey, Guildford, United KingdomUniversity of Balamand, Tripoli, LebanonCentre Hospitalier du Nord, Zgharta, LebanonTufts Medical Center, Boston, MA,United StatesIntroduction: The aim of this work was to study the ability of ciprofloxacin to restrict the development of resistant mutants of Escherichia coli and Klebsiella pneumoniae through determination of the Mutant Prevention Concentration (MPC). Methodology: We studied 140 strains of E. coli and 86 strains of K. pneumoniae with different profiles of sensitivity to fluoroquinolones and extended spectrum beta lactamase (ESBL) production. The MPCs were determined using an inoculum of 1010 CFU/ml in Mueller-Hinton agar plates with serial concentrations of ciprofloxacin. Results: Ciprofloxacin-susceptible ESBL-producing strains showed a higher MPC for ciprofloxacin (P <0.001) than ciprofloxacin-susceptible non ESBL-producing strains, while ciprofloxacin-resistant ESBL-producing and non ESBL-producing strains did not significantly differ. The presence of qnr variants was associated with elevated MPCs. This was observed for both tested organisms. Conclusions: Our study helps to explain the frequent finding of resistance to fluoroquinolones in ESBL-producing strains. Consequently, the use of concentrations of ciprofloxacin higher than the MIC in order to prevent the recovery and growth of resistant mutants is recommended. https://jidc.org/index.php/journal/article/view/3164mutant prevention concentrationESBLciprofloxacinEscherichia coliKlebsiella pneumoniae
spellingShingle Ziad Daoud
Elie Salem Sokhn
Eid Azar
Khalil Masri
Shira Doron
Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
Journal of Infection in Developing Countries
mutant prevention concentration
ESBL
ciprofloxacin
Escherichia coli
Klebsiella pneumoniae
title Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
title_full Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
title_fullStr Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
title_full_unstemmed Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
title_short Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae
title_sort mutant prevention concentrations of ciprofloxacin against urinary isolates of escherichia coli and klebsiella pneumoniae
topic mutant prevention concentration
ESBL
ciprofloxacin
Escherichia coli
Klebsiella pneumoniae
url https://jidc.org/index.php/journal/article/view/3164
work_keys_str_mv AT ziaddaoud mutantpreventionconcentrationsofciprofloxacinagainsturinaryisolatesofescherichiacoliandklebsiellapneumoniae
AT eliesalemsokhn mutantpreventionconcentrationsofciprofloxacinagainsturinaryisolatesofescherichiacoliandklebsiellapneumoniae
AT eidazar mutantpreventionconcentrationsofciprofloxacinagainsturinaryisolatesofescherichiacoliandklebsiellapneumoniae
AT khalilmasri mutantpreventionconcentrationsofciprofloxacinagainsturinaryisolatesofescherichiacoliandklebsiellapneumoniae
AT shiradoron mutantpreventionconcentrationsofciprofloxacinagainsturinaryisolatesofescherichiacoliandklebsiellapneumoniae